BRIEF-Modeyso™ (dordaviprone) Added to NCCN Guidelines for H3 K27M-Mutant Diffuse Glioma
Reuters
Sep 09
BRIEF-Modeyso™ (dordaviprone) Added to NCCN Guidelines for H3 K27M-Mutant Diffuse Glioma
Sept 9 (Reuters) - Jazz Pharmaceuticals PLCJAZZ.O:
MODEYSO™ (DORDAVIPRONE) INCLUDED IN NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CLINICAL PRACTICE GUIDELINES IN ONCOLOGY FOR H3 K27M-MUTANT DIFFUSE GLIOMA
Source text: ID:nPn7tp6hqa
Further company coverage: JAZZ.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.